Clinical trial
Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen
NCT00354263 · Immutep S.A.S., Industry · Completed
Key facts
| NCT number | NCT00354263 |
|---|---|
| Title | Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen |
| Official title | IMP321 Phase I Study of Four Increasing Doses (3, 10, 30 and 100 µg) of a New Immunostimulatory Factor (IMP321) Given Alone or as an Adjuvant to a Reference Flu Antigen in Healthy Young Male Volunteers |
| Lead sponsor | Immutep S.A.S., Industry |
| Collaborators | SGS Aster-Cephac (CRO) |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Biological |
| Interventions | IMP321, saline |
| Enrollment | 60 |
| Start date | Apr 1, 2005 |
| Primary completion | Sep 1, 2005 |
| Completion | Feb 1, 2006 |
| First posted | Jul 20, 2006 |
| Last update posted | Apr 24, 2008 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: